NCT02607124View on ClinicalTrials.gov

A Phase I/II Study of Ribociclib,a CDK4/6 Inhibitor, Following Radiation Therapy

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

May 31, 2018

Study Completion Date

August 31, 2018

Conditions
High Grade GliomaDiffuse Intrinsic Pontine GliomaBithalamic High Grade Glioma
Interventions
DRUG

Ribociclib

Trial Locations (1)

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Children's Hospital Medical Center, Cincinnati

OTHER

NCT02607124 - A Phase I/II Study of Ribociclib,a CDK4/6 Inhibitor, Following Radiation Therapy | Biotech Hunter | Biotech Hunter